A New Skin Biotech Keeps Human Tissue Alive for a Month to Hunt Better Ingredients

Outer Bio emerged from stealth in late August 2026 with $23 million and a bet that the key to better skincare — and possibly skin medicine — is keeping human skin alive in the laboratory far longer than anyone else can.

Co-founder and CEO Michael Polansky, who ran Sean Parker’s family office for 15 years and helped establish the Parker Institute for Cancer Immunotherapy, says the company keeps harvested human skin tissue functional for about a month — roughly 30 times longer than typical samples.

Why tissue survival time is the whole platform

The scientific claim rests entirely on that number, and it is worth understanding why it matters.

Skin biology is difficult to model. Cultured cells in a dish lack the layered architecture, immune components, blood vessels and mechanical structure of real skin. Engineered skin substitutes improve on that and remain simplifications. Animal skin differs meaningfully from human skin in thickness, structure and barrier properties.

Harvested human tissue is the closest available model, and it usually dies within a day or two. That is long enough to observe an acute reaction and useless for anything requiring time — and most interesting skin biology takes time. Barrier repair, pigmentation changes, collagen remodelling, inflammatory resolution all unfold over days to weeks.

Extending viability to a month converts the model from a snapshot into an experiment.

What they do with it

On that living tissue, Outer Bio screens millions of compounds using AI to identify new skincare ingredients and treatments for skin conditions.

The platform generates 30,000+ data points per compound-sample pairing, amassing over 10 terabytes across 300+ donors and 10,000 candidate treatments.

The donor count matters more than the compound count. Skin varies enormously between people — by age, pigmentation, sun exposure, barrier function and underlying condition — and testing across 300+ donors captures variation that a handful of cell lines cannot. A compound working on average is less useful than knowing which skin types it works on.

The deliberate positioning

Polansky is steering Outer away from traditional pharmaceutical timelines and regulatory burden, prioritising cosmetic and over-the-counter pathways — while staying open to drug applications if the data are compelling.

That is a considered strategic choice rather than an evasion. A prescription dermatology drug requires clinical trials, an approval process and roughly a decade before revenue. A cosmetic ingredient can reach market far faster, generating revenue and — importantly — real-world data while the platform matures.

Skincare is also an enormous market largely built on ingredients with thin evidence. A company able to demonstrate genuine effects on living human tissue has a real differentiator in a category where claims typically outrun data.

The obvious criticism

The cosmetic route is also the one with the lowest evidentiary bar. Cosmetic products are regulated far more loosely than drugs, cannot make therapeutic claims, and do not require efficacy demonstration before sale.

So a company can build a sophisticated screening platform and commercialise through a channel that never tests whether the output works in people. The tissue model may be excellent and still leave the central question — does this ingredient do anything on a living person over months — unanswered.

The honest version of the strategy is that cosmetic revenue funds a platform whose scientific value would be proven by the harder drug applications, if those come.

The backers, and the unusual board

Investors include Wing Venture Capital, Initialized Capital, Sozo Ventures and Polansky’s own Hawktail. The company partners with Haus Labs, Lady Gaga’s makeup brand, and both Polansky and Lady Gaga sit on its board.

The celebrity brand partnership is commercially coherent rather than decorative: it supplies a route to market and consumer credibility that a platform company would otherwise have to build.

Outer Bio employs 19 people and has posted preprints on its tissue-preservation method — a reasonable signal, since a company whose entire claim rests on tissue viability should be willing to describe how it achieves it.

The underlying argument

“Biology is super complicated,” Polansky said — a nod to why keeping real, living skin in the loop might beat simpler models.

The data asset may be the real product

Worth considering what a company accumulates when it runs millions of compounds across hundreds of donors on living tissue: 10 terabytes across 300+ donors and 10,000 candidate treatments is a dataset with properties that individual ingredient discoveries do not have.

Datasets of that shape — systematic, generated under consistent conditions, spanning wide biological variation — are exactly what machine learning models need and exactly what the field mostly lacks. Published skin biology data is fragmented across studies with different methods, endpoints and models, which makes it poor training material.

A proprietary, internally consistent corpus is therefore an asset that compounds: every additional compound tested improves the model predicting the next one, and competitors cannot replicate it without rebuilding the tissue platform first. That may prove more durable than any particular ingredient the screening produces — and it explains why investors would back a company whose stated near-term market is cosmetics.

That is the substantive thesis, and it runs against a prevailing direction of travel. Much of the industry is moving toward computational prediction and simplified high-throughput systems. Outer Bio is arguing the opposite: that skin is complicated enough that the model has to stay complicated, and the innovation is in keeping the complicated model alive. Business news, not investment advice.